Produkty 1343402-73-2

CAS 1343402-73-2 występuje w naszej ofercie pod nazwami: 3α-Hydroxymogrol, 3α-Hydroxymogrol, 99.88%, 99.88%, 3α-Hydroxymogrol, 99.88%. Oferty producentów: Biosynth, Chemat, MedChemExpress. Dostępne opakowania: 10mg, 5mg, 25mg, 50mg, 1mg, 20mg, 5 mg, 10 mg.

3α-Hydroxymogrol
Biosynth
  • opakowanie: 10mg, 5mg, 25mg, 50mg
  • Warianty: 4
Zobacz produkt
3α-Hydroxymogrol, 99.88%, 99.88%
Chemat
  • opakowanie: 1mg, 20mg
  • Warianty: 2
od 3102,80
Zobacz produkt
3α-Hydroxymogrol, 99.88%
MedChemExpress
  • opakowanie: 5 mg, 10 mg
  • Warianty: 2
od 3064,30
Zobacz produkt
Wzór strukturalny: {0} (CAS {1})

(3R,8S,9R,10R,11R,13R,14S,17R)-17-[(2R,5R)-5,6-dihydroxy-6-methylheptan-2-yl]-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3,11-diol (CAS 1343402-73-2) to związek chemiczny o wzorze sumarycznym C30H52O4 i masie molowej 476.7 g/mol. Nazwa systematyczna IUPAC: (3R,8S,9R,10R,11R,13R,14S,17R)-17-[(2R,5R)-5,6-dihydroxy-6-methylheptan-2-yl]-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3,11-diol. InChIKey: JLYBBRAAICDTIS-HYBNOKSXSA-N.

Dane identyfikacyjne
Wzór sumarycznyC30H52O4
Masa molowa476.7 g/mol
Nazwa IUPAC(3R,8S,9R,10R,11R,13R,14S,17R)-17-[(2R,5R)-5,6-dihydroxy-6-methylheptan-2-yl]-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3,11-diol
InChIKeyJLYBBRAAICDTIS-HYBNOKSXSA-N
SMILESC[C@H](CC[C@H](C(C)(C)O)O)[C@H]1CC[C@@]2([C@@]1(C[C@H]([C@@]3([C@H]2CC=C4[C@H]3CC[C@H](C4(C)C)O)C)O)C)C

Dane obliczone przez PubChem (NCBI)

Synonimy: 3Alpha-Hydroxymogrol, 3|A-Hydroxymogrol, 3??-Hydroxymogrol, 3| cent-Hydroxymogrol, orb1710579
Powiązane formy tego związku
(3S,8S,9R,10R,11R,13R,14S,17R)-17-[(2R,5R)-5,6-dihydroxy-6-methylheptan-2-yl]-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3,11-diol C30H52O4
Izomery (ten sam wzór sumaryczny)
(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,6,12-triol C30H52O4
(3S,5R,6R,8R,9R,10R,12R,13R,14R,17S)-4,4,8,10,14-pentamethyl-17-[(2R)-2,6,6-trimethyloxan-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,6,12-triol C30H52O4
(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,6,12-triol C30H52O4
[(20S)-20-methyldocosyl] 2,3-dihydroxybenzoate C30H52O4
(8R,10R,14R)-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,6,12-triol C30H52O4
(3R,5aR,6R,7S,9aR)-6-[2-[(1R,3aR,5S,8aR)-1-hydroxy-1,4,4,6-tetramethyl-2,3,3a,5,8,8a-hexahydroazulen-5-yl]ethyl]-2,2,5a,7-tetramethyl-4,5,6,8,9,9a-hexahydro-3H-benzo[b]oxepine-3,7-diol C30H52O4
(3S,5R,8R,9R,10R,12R,13R,14R,17S)-17-[(2S,5R)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,12-diol C30H52O4
(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-[(E)-6-hydroxy-6-methylhept-2-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,6,12-triol C30H52O4
(3R,3aS,4S,5aR,5bR,7S,7aR,9S,11aR,11bR,13aR,13bR)-3-(2-hydroxypropan-2-yl)-5a,5b,8,8,11a,13b-hexamethyl-1,2,3,3a,4,5,6,7,7a,9,10,11,11b,12,13,13a-hexadecahydrocyclopenta[a]chrysene-4,7,9-triol C30H52O4